Sierra Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRRA research report →
About the company
Sierra Oncology, Inc. is a biopharmaceutical firm focused on the late-stage research, development, and commercialization of therapeutic solutions for patients with blood disorders and various cancers. The company's primary drug candidate is momelotinib, an orally administered, selective inhibitor that targets Janus kinase 1 (JAK1), JAK2, and Activin A receptor type 1 (ACVR1).
- CEO
- Nicholas Glover
- IPO
- 2015
- Employees
- 109
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $0
- P/E
- -7.70
- P/S
- 0.00
- P/B
- 7.59
- EV/EBITDA
- 1.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -97.61%
- ROIC
- -97.74%
- Revenue
- $0 · -100.00%
- Net Income
- $-94,659,000 · -17.00%
- EPS
- $-7.14 · 7.27%
- Op Income
- $-94,662,000
- FCF YoY
- -50.89%
- 52W High
- $55.19
- 52W Low
- $14.91
- 50D MA
- $54.73
- 200D MA
- $33.69
- Beta
- 0.02
- Avg Volume
- 651.46K
Get TickerSpark's AI analysis on SRRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 22 | Vivo Opportunity, LLC | sell | 75,749 |
| Jul 1, 22 | Vivo Opportunity, LLC | sell | 431,947 |
| Jul 1, 22 | ORBIMED ADVISORS LLC | sell | 170,437 |
| Jul 1, 22 | ORBIMED ADVISORS LLC | sell | 226,704 |
| Jul 1, 22 | Ashiya Mona | sell | 170,437 |
| Jul 1, 22 | Ashiya Mona | sell | 1,500 |
| Jul 1, 22 | Ashiya Mona | sell | 6,000 |
| Jul 1, 22 | Ashiya Mona | sell | 6,874 |
| Jul 1, 22 | Ashiya Mona | sell | 226,704 |
| Jul 1, 22 | Sinclair Andrew | sell | 6,000 |
Our SRRA coverage
Recent articles, reports, and earnings notes.
No research on SRRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRRA report →Similar companies
Peers in the same neighborhood.